DUALITY BIOLOGICS
“To Translate Novel Modality into Reality”. Duality Biologics was founded in January 2020 by Dr. John Zhu, a well-respected investor in the healthcare industry. Duality Bio is committed to developing novel modality drugs to fulfill the unmet medical needs for patients worldwide. Focusing on the oncology and autoimmune diseases, the company has built a novel internal pipeline including nearly 10 Best-in-Class and First-in-Class bispecific antibody and Antibody-Drug Conjugate (ADC) drugs, of which several drug candidates are in the IND stage. The company has successfully built the next-generation ADC platform with global intellectual property rights. The value of this platform has been validated by a number of drug candidates under development.
DUALITY BIOLOGICS
Social Links:
Industry:
Biopharma Biotechnology Health Care Medical
Founded:
2020-01-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.dualitybiologics.com
Total Employee:
11+
Status:
Closed
Email Addresses:
[email protected]
Total Funding:
90 M USD
Similar Organizations
Dare Bioscience
Daré Bioscience is a healthcare company committed to the development and commercialization of innovative products.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
OnQuality Pharmaceuticals
OnQuality Pharmaceuticals involves in development and commercialization of innovative drugs and drug delivery systems.
TOT BIOPHARM
TOT BIOPHARM is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs.
Current Employees Featured
Founder
Investors List
Oriza Holdings
Oriza Holdings investment in Series B - Duality Biologics
Lilly Asia Ventures
Lilly Asia Ventures investment in Series B - Duality Biologics
Huagai Capital
Huagai Capital investment in Series B - Duality Biologics
WuXi Biologics
WuXi Biologics investment in Series B - Duality Biologics
Green Pine Capital Partners
Green Pine Capital Partners investment in Series B - Duality Biologics
NRL Capital
NRL Capital investment in Series B - Duality Biologics
Official Site Inspections
http://www.dualitybiologics.com
- Host name: 223.166.75.128
- IP address: 223.166.75.128
- Location: Shanghai China
- Latitude: 31.0449
- Longitude: 121.4012
- Timezone: Asia/Shanghai
More informations about "Duality Biologics"
Duality Biologics
Duality Bio is a biotech company based in China. Our mission is to become the development and commercialization engine house for next generation biologics, and to provide innovative …See details»
Duality Biologics-Duality Biologics
DualityBio is a clinical stage company focusing on the discovery and development of the next generation ADC therapeutics to treat patients in cancer and autoimmune diseases.See details»
Duality Biologics - Crunchbase Company Profile & Funding
Duality Biologics is a company focusing on the discovery, development and commercialization of new modality biologics to provide solutions. View contacts for Duality Biologics to access new …See details»
DualityBio Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for DualityBio.See details»
DualityBio Receives "Best New Drug Developer" at 2024 World …
Nov 8, 2024 · At the 15th World ADC San Diego conference, held from November 4-7, 2024, Duality Biologics (“DualityBio”) was awarded the "Best New Drug Developer" title, following …See details»
BioNTech and DualityBio Receive FDA Fast Track Designation for …
Jan 31, 2024 · MAINZ, Germany and SHANGHAI, China, January 31, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today …See details»
BioNTech and DualityBio Receive FDA Breakthrough Therapy …
Dec 21, 2023 · MAINZ, Germany and SHANGHAI, China, December 21, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”) today …See details»
BeiGene and DualityBio Announce Partnership to Advance …
Jul 10, 2023 · BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support …See details»
Duality Biologics Announces License Agreement of its Next …
Jan 5, 2023 · PRINCETON, N.J., SHANGHAI and SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Duality Biologics ("Duality"), a clinical-stage biotech company focused on discovering and …See details»
BioNTech moves into ADCs with Duality deal - BioPharma Dive
Apr 3, 2023 · BioNTech is expanding its cancer medicine pipeline in a new direction, announcing Monday a licensing deal with the China-based Duality Biologics that will give it access to two …See details»
BioNTech and DualityBio Form Global Strategic Partnership to …
Apr 3, 2023 · MAINZ, Germany and SHANGHAI, China, April 3, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”), a clinical-stage …See details»
BioNTech and DualityBio Form Global Strategic Partnership to …
Apr 3, 2023 · MAINZ, Germany and SHANGHAI, China, April 3, 2023 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”), a clinical-stage …See details»
Duality Biologics Completed $90 Million Series B Financing
May 19, 2021 · Focusing on the field of oncology and autoimmune diseases, DualityBio has developed a novel internal pipeline of nearly 10 Best-in-Class and First-in-Class bispecific …See details»
Duality Biologics Completed $90 Million Series B Financing - PR …
May 20, 2021 · Focusing on the field of oncology and autoimmune diseases, DualityBio has developed a novel internal pipeline of nearly 10 Best-in-Class and First-in-Class bispecific …See details»
BeiGene and DualityBio Announce Partnership to Advance …
Jul 10, 2023 · DualityBio is a clinical-stage company focusing on the discovery and development of the next generation ADC therapeutics for patients with cancer and autoimmune diseases. …See details»
BioNTech Inks Potential $1.5 Billion+ ADC Deal with Duality Biologics
Apr 3, 2023 · BioNTech is adding ADCs to its portfolio through a deal with China-based Duality Biologics (DualityBio). The two companies will collaborate on development, manufacturing, …See details»
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody …
MAINZ, Germany and SHANGHAI, China, January 22, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the …See details»